Covid-19 Cepiva

Ytbnd

Guru
2. mar 2010
16.789
5.918
113
Does the FDA think these data justify the first full approval of a covid-19 vaccine?
Luknje, veliko lukenj.
And so the recent reports from Israel’s Ministry of Health caught my eye. In early July, they reported that efficacy against infection and symptomatic disease “fell to 64%.” By late July it had fallen to 39% where Delta is the dominant strain. This is very low. For context, the FDA’s expectation is of “at least 50%” efficacy for any approvable vaccine.
Now Israel, which almost exclusively used Pfizer vaccine, has begun administering a third “booster” dose to all adults over 40. And starting 20 September 2021, the US plans to follow suit for all “fully vaccinated” adults eight months past their second dose.


Vs
And it’s hard to imagine how the Delta variant could play a real role here, for 77% of trial participants were from the United States, where Delta was not established until months after data cut-off.

Until new clinical trials demonstrate that boosters increase efficacy above 50%, without increasing serious adverse events, it is unclear whether the 2-dose series would even meet the FDA’s approval standard at six or nine months.
 
Nazadnje urejeno:

luka51

Guru
16. avg 2007
14.392
5.674
113
Khm, poglej moja zadnja dva posta.
Daj jih še ti za hec.
Predvem ta dva dela:
-The study found that vaccination with influenza vaccines containing the 2009 H1N1 virus strain used in the United States was not associated with an increased risk for narcolepsy.
- In 2018, a study team including CDC scientists analyzed and published vaccine safety data on adjuvanted pH1N1 vaccines (arenaprix-AS03, Focetria-MF59, and Pandemrix-AS03) from 10 global study sites. Researchers did not detect any associations between the vaccines and narcolepsy.
 

ynos

Vremenko
18. jul 2007
24.409
3.801
113
davorinm.wordpress.com
Ena za AndY1 , ziher znas utemeljiti.

0722AEDB-35BE-478F-A5E8-2A130CD6F409.jpeg
 

BojanP

200. registrirani uporabnik
24. jul 2007
3.922
2.633
113
Je že na prejšni strani. Da on ga je kupil iz indije za 55usd s poštnino in tako povzročil kaznivo dejanje.
 

Ytbnd

Guru
2. mar 2010
16.789
5.918
113
ynos
12 EUR zavitek
Zgornja cena je tipično vojno dobičkarstvo.


Cene v Grčiji, random online lekarna
40 tablet za ~pol zgornje cene
 
Nazadnje urejeno:

AndY1

Guru
Osebje foruma
18. sep 2007
22.082
4.080
113
The SARS-CoV-2 Delta variant is poised to acquire complete
resistance to wild-type spike vaccines


Abstract:
mRNA-based vaccines provide effective protection against most common SARS-CoV-2 variants.
However, identifying likely breakthrough variants is critical for future vaccine development. Here,
we found that the Delta variant completely escaped from anti-N-terminal domain (NTD)
neutralizing antibodies, while increasing responsiveness to anti-NTD infectivity-enhancing
antibodies. Although Pfizer-BioNTech BNT162b2-immune sera neutralized the Delta variant,
when four common mutations were introduced into the receptor binding domain (RBD) of the
Delta variant (Delta 4+), some BNT162b2-immune sera lost neutralizing activity and enhanced the
infectivity. Unique mutations in the Delta NTD were involved in the enhanced infectivity by the
BNT162b2-immune sera. Sera of mice immunized by Delta spike, but not wild-type spike,
consistently neutralized the Delta 4+ variant without enhancing infectivity. Given the fact that a
Delta variant with three similar RBD mutations has already emerged according to the GISAID
database, it is necessary to develop vaccines that protect against such complete breakthrough
variants.
 
19. jul 2007
2.834
1.553
113
Najnovejša Pfizerjeva študija o njihovem cepivu in o učunkovitosti (> 3 mio cepljenih).

Par povzetkov:
- bolj kakor delta sama ima vpliv pojemajoča imunost zaradi cepiv, prvi mesec zaščita 88 %, po petih mesecih pade na 47 %.
- pri delti je zaščita prvi mesec 93 %, že po 4 mesecih pade na 53 % (samo za občutek, interval zaupanja je 39 % - 65 %)

Findings: For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95%CI: 72‒74) and against COVID-19-related hospitalizations was 90% (89‒92). Effectiveness against infections declined from 88% (86‒89) during the first month after full vaccination to 47% (43‒51) after ≥5 months. Among sequenced infections, VE against Delta was lower compared to VE against other variants (75% [71‒78] vs 91% [88‒92]). VE against Delta infections was high during the first month after full vaccination (93% [85‒97]) but declined to 53% [39‒65] at ≥4 months. VE against hospitalization for Delta for all ages was high overall (93%).
1629835672501.png
 
  • Všeč mi je
Reactions: AndY1

kalbo

Guru
7. okt 2013
18.671
9.469
113
Ni, po tistem, ko je zbrisal z vrste, je postal hard core antiwakser in že celo večnost googla nebuloze.
 

AndY1

Guru
Osebje foruma
18. sep 2007
22.082
4.080
113
Najnovejša Pfizerjeva študija o njihovem cepivu in o učunkovitosti (> 3 mio cepljenih).

Par povzetkov:
- bolj kakor delta sama ima vpliv pojemajoča imunost zaradi cepiv, prvi mesec zaščita 88 %, po petih mesecih pade na 47 %.
- pri delti je zaščita prvi mesec 93 %, že po 4 mesecih pade na 53 % (samo za občutek, interval zaupanja je 39 % - 65 %)

Findings: For fully vaccinated individuals, effectiveness against SARS-CoV-2 infections was 73% (95%CI: 72‒74) and against COVID-19-related hospitalizations was 90% (89‒92). Effectiveness against infections declined from 88% (86‒89) during the first month after full vaccination to 47% (43‒51) after ≥5 months. Among sequenced infections, VE against Delta was lower compared to VE against other variants (75% [71‒78] vs 91% [88‒92]). VE against Delta infections was high during the first month after full vaccination (93% [85‒97]) but declined to 53% [39‒65] at ≥4 months. VE against hospitalization for Delta for all ages was high overall (93%).
Poglej priponko 47914
Torej drži to, kar sem pred kratkim polinkal, da je učinkovitost Pfizerjevega cepiva po 6 mesecih proti Delta sevu le še 36%. Karkoli pod 50% pa pade izven EUA odobritve - očitno že po 4 mesecih, po tvojih podatkih.